Results 11 to 20 of about 46,300 (164)

Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases

Frontiers in Synaptic Neuroscience, 2022
Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors. A major pathological feature of both Alzheimer’s dis-ease (AD) and Parkinson’s disease (PD) is the loss of synaptic transmission ...
Christian Hölscher
doaj   +1 more source

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle [PDF]

, 2015
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
Alloosh, Mouhamad, Bell, Lauren N., Chalasani, Naga, Dineen, Stacey L., Fullenkamp, Allison M., McKenney, Mikaela L., Schultz, Kyle A., Sturek, Michael   +7 more
core   +1 more source

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease

Kidney and Dialysis, 2022
Diabetic kidney disease (DKD) represents an important diabetes (DM) complication associated with significant impacts on morbidity, mortality, and quality of life. Recent evidence from cardiovascular and kidney outcome trials has dramatically impacted the
Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle   +2 more
doaj   +1 more source

When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]

, 2016
Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier, Cohen, Ohad, FILETTI, SEBASTIANO, Glandt, Mariela, MARANGHI, MARIANNA   +4 more
core   +2 more sources

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +5 more sources

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond, Watterson, Kenneth R.   +3 more
core   +2 more sources

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source

Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]

, 2015
AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo, Dagostino, Mariangela Pia, Fallarino, Mara, Filardi, Tiziana, Lenzi, Andrea, Mandosi, Elisabetta, Morano, Susanna, Nieddu, Luciano, Romagnoli, Elisabetta, Turinese, Irene   +9 more
core   +1 more source

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation [PDF]

, 2016
The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion.
A Bond, A Thompson, A Thompson, A Thompson, A Thompson, AC Hanyaloglu, Aiysha Thompson, B Thorens, BD Green, C Koole, C Montrose-Rafizadeh, C Orskov, CE Groer, CR Underwood, D Wootten, D Wootten, DJ Drucker, FS Willard, FS Willard, GG Holz, JC Davies, JC Davies, Jeffrey W. Stephens, JT Patterson, K Coopman, K Venkateswarlu, K Zahn, KW Sloop, L Ma, LB Knudsen, M Edavalath, ME Doyle, MR Price, N Irwin, N Li, P Vazquez, R Goke, R López de Maturana, Rasheed Ahmad, RL Thomas, RS Kuna, S Takhar, SK Mathi, SN Roed, Stephen C. Bain, T Kim Chung le, TM Bridges, TP Vahl, V Kanamarlapudi, V Serre, Venkateswarlu Kanamarlapudi, WM Nolte, YH Cheong   +52 more
core   +5 more sources